GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » Price-to-Operating-Cash-Flow

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Apr. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Recursion Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-04-28), Recursion Pharmaceuticals's share price is $8.12. Recursion Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.39. Hence, Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

RXRX's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 24.65
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Recursion Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.33. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.39.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -50.80% per year.

During the past 5 years, Recursion Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 2.10% per year. The lowest was -50.80% per year. And the median was -24.35% per year.


Recursion Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recursion Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
- - - - -

Recursion Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Recursion Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=8.12/-1.391
=

Recursion Pharmaceuticals's Share Price of today is $8.12.
Recursion Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Recursion Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Recursion Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Executives
Michael Secora officer: Chief Financial Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani officer: Chief Corp. Dev. Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson director, 10 percent owner, officer: Chief Executive Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson officer: President and COO C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar director C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc 10 percent owner P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert other: Former 10% Owner C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p. other: Former 10% Owner 295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc other: Former 10% Owner 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc other: Former 10% Owner C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p. other: Former 10% Owner C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010